ENVB

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Enveric Biosciences Inc

NASDAQ | ENVB

0.79

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$5.60M

Market Cap

-

P/E Ratio

-9.97

EPS

$124.88

52 Week High

$0.56

52 Week Low

HEALTHCARE

Sector

ENVB Chart

Recent Chart
Price Action

ENVB Technicals

Tags:

ENVB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$337K
Total Revenue $0
Cost Of Revenue $337K
Costof Goods And Services Sold $337K
Operating Income -$9.6M
Selling General And Administrative $6.5M
Research And Development $2.8M
Operating Expenses $9.3M
Investment Income Net -
Net Interest Income $219
Interest Income $219
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $337K
Income Before Tax -$9.6M
Income Tax Expense $8.9K
Interest And Debt Expense -
Net Income From Continuing Operations -$9.6M
Comprehensive Income Net Of Tax -
Ebit -$9.6M
Ebitda -$9.2M
Net Income -$9.6M

Revenue & Profitability

Earnings Performance

ENVB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $3.1M
Total Current Assets $2.7M
Cash And Cash Equivalents At Carrying Value $2.2M
Cash And Short Term Investments $2.2M
Inventory -
Current Net Receivables -
Total Non Current Assets $348K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $42K
Intangible Assets Excluding Goodwill $42K
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $494K
Other Non Current Assets -
Total Liabilities $1.5M
Total Current Liabilities $1.5M
Current Accounts Payable $522K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $0
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $707K
Other Non Current Liabilities -
Total Shareholder Equity $1.6M
Treasury Stock -
Retained Earnings -$106M
Common Stock $6.8K
Common Stock Shares Outstanding $503K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$7.7M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $337K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $7.7M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $1.1M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$9.6M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$337K
Total Revenue $0
Cost Of Revenue $337K
Costof Goods And Services Sold $337K
Operating Income -$9.6M
Selling General And Administrative $6.5M
Research And Development $2.8M
Operating Expenses $9.3M
Investment Income Net -
Net Interest Income $219
Interest Income $219
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $337K
Income Before Tax -$9.6M
Income Tax Expense $8.9K
Interest And Debt Expense -
Net Income From Continuing Operations -$9.6M
Comprehensive Income Net Of Tax -
Ebit -$9.6M
Ebitda -$9.2M
Net Income -$9.6M

ENVB News

ENVB Profile

Enveric Biosciences Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Enveric Biosciences Inc. is a pioneering pharmaceutical company based in Florida, dedicated to developing cannabinoid-based therapeutics that significantly improve treatment outcomes for cancer patients. By leveraging its deep expertise in cannabinoid research, Enveric is focused on creating innovative drug candidates that target unmet medical needs and enhance the quality of life for individuals battling cancer. With a strong emphasis on clinical development, the company is strategically positioned to capitalize on the expanding convergence of cannabinoid science and oncology, ultimately aiming to transform cancer care.

VHAI
-20.00%
$0.00
VIVK
-3.01%
$0.28
YYAI
-10.71%
$0.12
BURU
+2.88%
$0.34
NVDA
-0.11%
$179.83
EPWK
+16.29%
$0.08
CGBS
-39.47%
$0.03
BITF
-15.68%
$5.45
ADAP
+6.57%
$0.19
RXRX
-6.33%
$6.36
PLUG
-7.01%
$3.58
IVF
+129.44%
$1.73
YDKG
-55.45%
$0.08
NVTS
+4.35%
$15.82
BYND
-14.17%
$0.67
RGTI
-12.76%
$49.15
DNN
-1.57%
$3.12
NIO
-1.09%
$6.74
MIRA
+29.16%
$1.70
SCNX
+0.26%
$0.71
BBD
+1.71%
$3.25
WHWK
+27.64%
$2.68
F
-0.63%
$11.68
ACHR
-7.36%
$12.07
TLRY
-8.41%
$1.53
TSLA
+1.37%
$435.15
IONZ
+18.46%
$3.41
AXDX
-61.36%
$0.03
INTC
-1.10%
$36.74
CAN
-14.28%
$1.68
HPE
-10.09%
$22.51
ONDS
-15.03%
$8.07
DFLI
-31.72%
$1.34
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
ETHD
+4.23%
$3.94
CLF
-3.39%
$13.47
GDXD
-8.97%
$0.60
BTG
+3.96%
$5.89
LAES
-15.15%
$6.35
AAL
-6.00%
$11.75
VSEE
-8.84%
$0.54
MARA
-10.98%
$20.32
GNPX
-47.58%
$0.44
RIG
-3.32%
$3.20
ABAT
-21.00%
$8.94
LGCB
+35.15%
$2.23
QBTS
-10.47%
$40.08
BTBT
-8.82%
$3.70
QS
-12.89%
$15.54
KVUE
-10.83%
$14.49
RF
-5.98%
$23.26
NAK
-16.47%
$2.20
QSI
-2.66%
$2.56
CRML
-13.51%
$19.64
RGTZ
+28.73%
$11.19
MASK
+16.15%
$0.56
RR
-6.38%
$5.76
CIFR
-10.08%
$18.91
UUUU
-11.06%
$22.22
CLSK
-13.92%
$19.97
FEMY
+31.43%
$0.72
RMBL
+60.50%
$3.21
IREN
-8.20%
$62.40
GPUS
-6.53%
$0.36
QUBT
-10.73%
$18.95
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOUN
-3.66%
$20.61
WOK
+1.03%
$0.05
AUUD
+3.41%
$2.12
SNAP
-3.53%
$7.63
MU
+4.60%
$200.77
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
SRM
+53.27%
$10.30
SOND
+78.80%
$1.64
PLTR
-0.81%
$178.16
WTO
-88.69%
$0.13
SMR
-7.73%
$49.29
TOVX
-47.86%
$0.43
FNB
-8.00%
$14.52
KDLY
+1.29%
$0.79
JBLU
-4.94%
$4.70
AMZN
-0.81%
$213.82
SLNH
+1.86%
$4.37
HIMS
-6.07%
$58.94
NOK
+0.44%
$5.67
HBAN
-4.62%
$15.46
WULF
-8.82%
$14.10
SATL
-27.65%
$2.99
AMC
-1.77%
$2.77
ELWS
+48.09%
$5.45
GGB
-0.46%
$3.24
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
PFE
-0.12%
$24.35
KEY
-6.45%
$16.58
WLGS
-5.57%
$0.04
BAC
-2.83%
$50.80
VHAI
-20.00%
$0.00
VIVK
-3.01%
$0.28
YYAI
-10.71%
$0.12
BURU
+2.88%
$0.34
NVDA
-0.11%
$179.83
EPWK
+16.29%
$0.08
CGBS
-39.47%
$0.03
BITF
-15.68%
$5.45
ADAP
+6.57%
$0.19
RXRX
-6.33%
$6.36
PLUG
-7.01%
$3.58
IVF
+129.44%
$1.73
YDKG
-55.45%
$0.08
NVTS
+4.35%
$15.82
BYND
-14.17%
$0.67
RGTI
-12.76%
$49.15
DNN
-1.57%
$3.12
NIO
-1.09%
$6.74
MIRA
+29.16%
$1.70
SCNX
+0.26%
$0.71
BBD
+1.71%
$3.25
WHWK
+27.64%
$2.68
F
-0.63%
$11.68
ACHR
-7.36%
$12.07
TLRY
-8.41%
$1.53
TSLA
+1.37%
$435.15
IONZ
+18.46%
$3.41
AXDX
-61.36%
$0.03
INTC
-1.10%
$36.74
CAN
-14.28%
$1.68
HPE
-10.09%
$22.51
ONDS
-15.03%
$8.07
DFLI
-31.72%
$1.34
AMD
-1.33%
$235.40
SOFI
-6.13%
$26.31
ETHD
+4.23%
$3.94
CLF
-3.39%
$13.47
GDXD
-8.97%
$0.60
BTG
+3.96%
$5.89
LAES
-15.15%
$6.35
AAL
-6.00%
$11.75
VSEE
-8.84%
$0.54
MARA
-10.98%
$20.32
GNPX
-47.58%
$0.44
RIG
-3.32%
$3.20
ABAT
-21.00%
$8.94
LGCB
+35.15%
$2.23
QBTS
-10.47%
$40.08
BTBT
-8.82%
$3.70
QS
-12.89%
$15.54
KVUE
-10.83%
$14.49
RF
-5.98%
$23.26
NAK
-16.47%
$2.20
QSI
-2.66%
$2.56
CRML
-13.51%
$19.64
RGTZ
+28.73%
$11.19
MASK
+16.15%
$0.56
RR
-6.38%
$5.76
CIFR
-10.08%
$18.91
UUUU
-11.06%
$22.22
CLSK
-13.92%
$19.97
FEMY
+31.43%
$0.72
RMBL
+60.50%
$3.21
IREN
-8.20%
$62.40
GPUS
-6.53%
$0.36
QUBT
-10.73%
$18.95
ASST
-11.57%
$0.84
ADD
-25.47%
$0.05
SOUN
-3.66%
$20.61
WOK
+1.03%
$0.05
AUUD
+3.41%
$2.12
SNAP
-3.53%
$7.63
MU
+4.60%
$200.77
APLD
-1.69%
$37.11
NEHC
+9.12%
$3.35
SRM
+53.27%
$10.30
SOND
+78.80%
$1.64
PLTR
-0.81%
$178.16
WTO
-88.69%
$0.13
SMR
-7.73%
$49.29
TOVX
-47.86%
$0.43
FNB
-8.00%
$14.52
KDLY
+1.29%
$0.79
JBLU
-4.94%
$4.70
AMZN
-0.81%
$213.82
SLNH
+1.86%
$4.37
HIMS
-6.07%
$58.94
NOK
+0.44%
$5.67
HBAN
-4.62%
$15.46
WULF
-8.82%
$14.10
SATL
-27.65%
$2.99
AMC
-1.77%
$2.77
ELWS
+48.09%
$5.45
GGB
-0.46%
$3.24
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
PFE
-0.12%
$24.35
KEY
-6.45%
$16.58
WLGS
-5.57%
$0.04
BAC
-2.83%
$50.80
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.